当前位置:
首页
网刊
基于深度测序的循环肿瘤DNA检测在肿瘤诊治中的应用进展
基于深度测序的循环肿瘤DNA检测在肿瘤诊治中的应用进展
周春莲,徐伟文

南方医科大学检验与生物技术学院抗体工程研究所,广州 510515
The application of circulating tumor DNA assay based on deep  sequencing in cancer diagnosis and treatment
(Institute of Antibody Engineering, School of Laboratory Medicine and Biotechnology,  Southern Medical University, Guangzhou 510515, China)

摘要参考文献相关文章

起始页:2401

摘要:[摘要] 循环肿瘤DNA为血液中与肿瘤相关的游离核酸,可作为肿瘤诊治的标志物。基于深度测序的循环肿瘤DNA检测在肿瘤诊治中具有高通量、高灵敏度、微创、一定程度上能克服肿瘤异质性等优势,在评估肿瘤动态和肿瘤负荷、检测微小残留病灶和复发风险预测、个体化用药指导和预后评估等方面显示出很高的价值。本文将对基于深度测序的循环肿瘤DNA检测在肿瘤诊治中的应用做一综述。

关键词:[关键词] 深度测序;循环肿瘤 DNA;肿瘤标志物;靶向治疗;液体活检

通讯作者:

基金项目:

作者简介:

Abstract:[Abstract] Circulating tumor DNA has evolved to be a promising noninvasive marker of tumor evaluation. Monitoring circulating tumor DNA with deep sequencing-based assays has lots of advantages and applications. The advantages include ultra-sensitivity and specificity, noninvasiveness and less heterogeneity. The applications include monitoring of tumor burden, monitoring of minimal residual disease and recurrence, personalized treatment and assessment of prognosis of tumor. In this article, we reviewed the clinical applications of deep sequencing-based circulating tumor DNA assay.

Key words:[Key words] deep sequencing;circulating tumor DNA;tumor biomarkers;targeted therapy; liquid biopsy

    [1] MANDEL PMP. Les acides nucléiques du plasma sanguin chez l'homme[J]. CR Acad Sci Paris, 1948, 142(3-4): 241-243.
    [2] GARCIA-OLMO DC, DOMINGUEZ C, GARCIA-ARRANZ M, et al. Cell-free nucleic acids circulating in the plasma of colorectalcancer patients induce the oncogenic transformation of susceptible cultured cells[J]. Cancer Res, 2010, 70(2): 560-567.
    [3] JAHR S, HENTZE H, ENGLISCH S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells[J]. Cancer Res, 2001, 61(4): 1659-1665.
    [4] STROUN M, LYAUTEY J, LEDERREY C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release[J]. Clin Chim Acta, 2001, 313(1-2): 139-142.
    [5] SIDRANSKY D. Emerging molecular markers of cancer[J]. Nat Rev Cancer, 2002, 2(3): 210-219.
    [6] YU SCY, JIANG P, ALLEN CHAN KC, et al. Combined count- and size-based analysis of maternal plasma DNA for noninvasive prenatal detection of fetal subchromosomal aberrations facilitates elucidation of the fetal and/or maternal origin of the aberrations[J]. Clin Chem, 2016, 21(3): 105-120.
    [7] JIANG P, LO YMD. The long and short of circulating cell-free DNA and the ins and outs of molecular diagnostics[J]. Trends Genet, 2016, 32(6): 360-371.
    [8] UNDERHILL HR, KITZMAN JO, HELLWIG S, et al. Fragment length of circulating tumor DNA[J]. Plos Genet, 2016, 12(7): e1006162.
    [9] DIAZ LA, BARDELLI A. Liquid biopsies: genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 32(6): 579-586.
    [10] LANMAN RB, MORTIMER SA, ZILL OA, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA[J]. Plos One, 2015, 10(10): e140712.
    [11] REINERT T, SCHLER LV, THOMSEN R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery[J]. Gut, 2016, 65(4): 625-634.
    [12] BETTEGOWDA C, SAUSEN M, LEARY RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224.
    [13] DAWSON SJ, ROSENFELD N, CALDAS C. Circulating tumor DNA to monitor metastatic breast cancer[J]. New Engl J Med, 2013, 369(1): 93-94.
    [14] FORSHEW T, MURTAZA M, PARKINSON C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA[J]. Sci Transl Med, 2012, 4(136): 136-168.
    [15] DIEHL F, SCHMIDT K, CHOTI MA, et al. Circulating mutant DNA to assess tumor dynamics[J]. Nat Med, 2008, 14(9): 985-990.
    [16] TAI DI, TSAI SL, CHANG YH, et al. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma[J]. Cancer-Am Cancer Soc, 2000, 89(11): 2274.
    [17] NEWTON CR, GRAHAM A, HEPTINSTALL LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)[J]. Nucleic Acids Res, 1989, 17(7): 2503-2516.
    [18] 邵向阳, 徐伟文. 下一代测序(NGS)技术的发展及在肿瘤研究的应用[J]. 分子诊断与治疗杂志, 2016,8(5): 289-296.
    [19] BRATMAN SV, NEWMAN AM, ALIZADEH AA, et al. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq[J]. Expert Rev Mol Diagn, 2015, 15(6): 1-5.
    [20] LV W, WEI X, GUO R, et al. Noninvasive prenatal testing for wilson disease by use of circulating single-molecule amplification and resequencing technology (cSMART)[J]. Clin Chem, 2014, 61(1): 172-181.
    [21] NEWMAN AM, LOVEJOY AF, KLASS DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA[J]. Nat Biotechnol, 2016, 34(5): 547-555.
    [22] 杨学习. 下一代测序技术在遗传病临床检测中的应用[J]. 分子诊断与治疗杂志, 2016,8(6): 357-362.
    [23] 戴五敏, 韩晓红, 石远凯. 循环肿瘤DNA在肿瘤临床应用中的进展[J]. 中国新药杂志, 2016,25(21): 2456-2461.
    [24] GUO N, LOU F, MA Y, et al. Circulating tumor DNA detection in lung cancer patients before and after surgery[J]. Sci Rep, 2016, 6: 33519.
    [25] HAMAKAWA T, KUKITA Y, KUROKAWA Y, et al. Monitoring gastric cancer progression with circulating tumour DNA[J]. Brit J Cancer, 2014, 112(2): 352-356.
    [26] TIE J, WANG Y, TOMASETTI C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer[J]. Sci Transl Med, 2016, 8(346): 346-392.
    [27] ONO A, FUJIMOTO A, YAMAMOTO Y, et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy[J]. Cell Mol Gastroenterolo Hepatol, 2015, 1(5): 516-534.
    [28] TURNER NC, GARCIA-MURILLAS I, SCHIAVON G, et al. Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after treatment of primary breast cancer[J]. J Clin Oncol, 2014, 32(15): 511.
    [29] ROSCHEWSKI M, STAUDT LM, WILSON WH. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma[J]. Blood, 2016, 127(25): 3127-3132.
    [30] IMAMURA F, UCHIDA J, KUKITA Y, et al. Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment[J]. Oncotarget, 2016, 7(44): 71782-71789.
    [31] ROSELL R, KARACHALIOU N. Lung cancer: using ctDNA to track EGFR and KRAS mutations in advanced-stage disease[J]. Nat Rev Clin Oncol, 2016, 13(7): 401-402.
    [32] JIN Y, SHAO Y, SHI X, et al. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing[J]. Oncotarget, 2016, 7(38): 61755-61763.
    [33] PIETRASZ D, PCUCHET N, GARLAN F, et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker[J]. Clin Cancer Res, 2017, 23(1): 116-123.
    [34] OCANA A, DIEZ-GONZALEZ L, GARCIA-OLMO DC, et al. Circulating DNA and survival in solid tumors[J]. Cancer Epidem Biomar, 2016, 25(2): 399-406.
    [35] LIAO W, YANG H, XU H, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing[J]. Oncotarget, 2016, 7(26): 40481-40490.